Article
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Pediatric pulmonology - 1 Sept 2020
Çobanoğlu Nazan, Özçelik Uğur, Çakır Erkan, Şişmanlar Eyüboğlu Tuğba, Pekcan Sevgi, Cinel Güzin, Yalçın Ebru, Kiper Nural, Emiralioğlu Nagehan, Şen Velat, Şen Hadice Selimoğlu, Ercan Ömür, Çokuğraş Haluk, Kılınç Ayşe Ayzıt, Al Shadfan Lina Muhammed, Yazan Hakan, Altıntaş Derya Ufuk, Karagöz Dilek, Demir Esen, Kartal Öztürk Gökçen, Bingöl Ayşen, Başaran Abdurrahman Erdem, Sapan Nihat, Çekiç Şükrü, Çelebioğlu Ebru, Aslan Ayşe Tana, Gürsoy Tuğba Ramaslı, Tuğcu Gökçen, Özdemir Ali, Harmancı Koray, Yıldırım Gonca Kılıç, Köse Mehmet, Hangül Melih, Tamay Zeynep, Süleyman Ayşe, Yüksel Hasan, Yılmaz Özge, Özcan Gizem, Topal Erdem, Can Demet, Korkmaz Ekren Pervin, Çaltepe Gönül, Kılıç Mehmet, Özdoğan Şebnem, Doğru Deniz
Abstract excerpt
BACKGROUND: A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs. METHODS: Data for age and genetic mutations from the Cystic Fibrosis...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.